ZA9610584B - Use of rc-9 in diagnosis and treatment of proliferative arterial disease - Google Patents

Use of rc-9 in diagnosis and treatment of proliferative arterial disease

Info

Publication number
ZA9610584B
ZA9610584B ZA9610584A ZA9610584A ZA9610584B ZA 9610584 B ZA9610584 B ZA 9610584B ZA 9610584 A ZA9610584 A ZA 9610584A ZA 9610584 A ZA9610584 A ZA 9610584A ZA 9610584 B ZA9610584 B ZA 9610584B
Authority
ZA
South Africa
Prior art keywords
diagnosis
treatment
arterial disease
proliferative
proliferative arterial
Prior art date
Application number
ZA9610584A
Inventor
Eliot Howard Ohlstein
Anthony Joseph Arleth
Michael Victor Aurieri
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA9610584B publication Critical patent/ZA9610584B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA9610584A 1995-12-18 1996-12-17 Use of rc-9 in diagnosis and treatment of proliferative arterial disease ZA9610584B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US880195P 1995-12-18 1995-12-18

Publications (1)

Publication Number Publication Date
ZA9610584B true ZA9610584B (en) 1997-06-23

Family

ID=21733759

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610584A ZA9610584B (en) 1995-12-18 1996-12-17 Use of rc-9 in diagnosis and treatment of proliferative arterial disease

Country Status (5)

Country Link
EP (1) EP0904543A1 (en)
JP (1) JP2000503764A (en)
AU (1) AU1413997A (en)
WO (1) WO1997022880A1 (en)
ZA (1) ZA9610584B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0879882A1 (en) * 1997-05-22 1998-11-25 Smithkline Beecham Corporation ATG-1100 (AIF-1-Gamma), a splice variant of AIF-1/RC-9
EP0879883A1 (en) * 1997-05-22 1998-11-25 Smithkline Beecham Corporation ATG-1120 (AIF-1-DELTA), a splice variant of AIF-1/RC-9
EP1383797A2 (en) * 2001-02-07 2004-01-28 Universiteit Maastricht Markers of unstable atherosclerotic plaques
WO2010018870A1 (en) 2008-08-15 2010-02-18 藤倉化成株式会社 Polypeptide marker for diagnosis of arteriosclerosis, method for detection of arteriosclerosis by using the maker or the like, and kit for diagnosis of arteriosclerosis

Also Published As

Publication number Publication date
EP0904543A1 (en) 1999-03-31
AU1413997A (en) 1997-07-14
WO1997022880A1 (en) 1997-06-26
JP2000503764A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
EP0963219A4 (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
SG49658A1 (en) Treatment of condition and disease
HU9602583D0 (en) Gel for treatment of skin diseases and for disinfection of the skin
NZ289028A (en) Use of antisense nucleic acids in the treatment of skin disease
GB9925804D0 (en) Biological materials and method useful in the diagnosis and treatment of diseases
ZA969217B (en) Skin care preparation and method
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
EP0506893A4 (en) Diagnosis and treatment of diseases
EP0831793A4 (en) Protein particles for therapeutic and diagnostic use
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
HUP9904294A3 (en) Topiramate derivatives and their use for producing medicament useful in the treatment of neuropathic pain
GB9321341D0 (en) Therapeutic compositions for use in the treatment of skin lesions and method of making same
ZA969470B (en) Melanoquaternary compounds and their use as hair dyes and for skin treatment
ZA952519B (en) Therapeutic use of hemoglobin in the treatment of blood vessel blockage
EP0888381A4 (en) Targeted therapeutic or diagnostic agents and methods of making and using same
ZA9610584B (en) Use of rc-9 in diagnosis and treatment of proliferative arterial disease
ZA968054B (en) Therapeutic use of hemoglobin in promoting wound healing
AU7316196A (en) Diagnosis of susceptibility to cancer and treatment thereof
GB9514816D0 (en) Substances and their medical use
GB9908059D0 (en) Diagnosis and treatment of diseases
EP0862442A4 (en) Methods for diagnosis and treatment of bloom's syndrome
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8
GB9406577D0 (en) Diagnosis and treatment of degenerative disease
GB9516572D0 (en) Prevention and/or treatment of disease
GB9520159D0 (en) Benzoioc amide retinoids for use in the treatment of skin diseases and cancer